Optimizing Treatment of Resistant/Refractory CMV Infection in Solid Organ Transplant Recipients

Program Overview

CMV is one of the most common opportunistic infections affecting solid organ transplant recipients (SOTRs), conveying higher risks of complications, graft loss, morbidity, and mortality. Treatment options for CMV are limited, have similar mechanisms of action, suffer from cross-resistance, and have serious toxicities. Until recently, no treatment option was available in the resistant/refractory setting. This workshop, developed in collaboration with The Transplantation Society (TTS) and Dr. Camille Kotton, MD, FIDSA, FAST, will take you through a CMV primer and then move on to discuss cases submitted by your peers from transplant centers across the United States.

Credit Expired

Target Audience

This activity is intended for clinicians practicing in transplantation, infectious disease, and nephrology.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Employ evidence-based antiviral treatment strategies for cytomegalovirus (CMV) in solid organ transplant (SOT) patients
  • Utilize antiviral resistance testing to identify SOT patients with treatment refractory or drug resistant CMV
  • Implement new treatment strategies in the management of resistant or refractory CMV in SOT patients


Activity Faculty

Camille Kotton portrait 2021

Camille Nelson Kotton, MD, FIDSA, FAST

Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources